Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib with Adjuvant Chemotherapy in Locally Advanced GI Tumors
NCT05742620Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Jun 2023
- Primary completion
- Jul 2026
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of anlotinib in gastric cancer (GC) and colorectal cancer (CRC), sponsored by Xijing Hospital. Primary endpoint: 3-year Disease-free survival rate. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
gastric cancer (GC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05742620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05742620.